324 related articles for article (PubMed ID: 19637007)
1. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.
Pizer BL; Clifford SC
Br J Neurosurg; 2009 Aug; 23(4):364-75. PubMed ID: 19637007
[TBL] [Abstract][Full Text] [Related]
2. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
3. Medulloblastoma: presentation, diagnosis and management.
Packer RJ; Finlay JL
Oncology (Williston Park); 1988 Sep; 2(9):35-45, 48-9. PubMed ID: 3275066
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91.
Rutkowski S; von Bueren A; von Hoff K; Hartmann W; Shalaby T; Deinlein F; Warmuth-Metz M; Soerensen N; Emser A; Bode U; Mittler U; Urban C; Benesch M; Kortmann RD; Schlegel PG; Kuehl J; Pietsch T; Grotzer M
Clin Cancer Res; 2007 May; 13(9):2651-7. PubMed ID: 17473196
[TBL] [Abstract][Full Text] [Related]
5. Clinical management of medulloblastoma in adults.
Eisenstat DD
Expert Rev Anticancer Ther; 2004 Oct; 4(5):795-802. PubMed ID: 15485314
[TBL] [Abstract][Full Text] [Related]
6. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
von Hoff K; Hartmann W; von Bueren AO; Gerber NU; Grotzer MA; Pietsch T; Rutkowski S
Pediatr Blood Cancer; 2010 Mar; 54(3):369-76. PubMed ID: 19908297
[TBL] [Abstract][Full Text] [Related]
7. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
8. [Childhood medulloblastoma].
Yazigi-Rivard L; Masserot C; Lachenaud J; Diebold-Pressac I; Aprahamian A; Avran D; Doz F
Arch Pediatr; 2008 Dec; 15(12):1794-804. PubMed ID: 18995998
[TBL] [Abstract][Full Text] [Related]
9. Stratification of medulloblastoma on the basis of histopathological grading.
Giangaspero F; Wellek S; Masuoka J; Gessi M; Kleihues P; Ohgaki H
Acta Neuropathol; 2006 Jul; 112(1):5-12. PubMed ID: 16685513
[TBL] [Abstract][Full Text] [Related]
10. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91--implications for investigating childhood medulloblastoma.
Grotzer MA; von Hoff K; von Bueren AO; Shalaby T; Hartmann W; Warmuth-Metz M; Emser A; Kortmann RD; Kuehl J; Pietsch T; Rutkowski S
Klin Padiatr; 2007; 219(6):312-7. PubMed ID: 18050040
[TBL] [Abstract][Full Text] [Related]
11. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.
Gajjar A; Hernan R; Kocak M; Fuller C; Lee Y; McKinnon PJ; Wallace D; Lau C; Chintagumpala M; Ashley DM; Kellie SJ; Kun L; Gilbertson RJ
J Clin Oncol; 2004 Mar; 22(6):984-93. PubMed ID: 14970185
[TBL] [Abstract][Full Text] [Related]
12. Risk-adapted chemotherapy in childhood medulloblastoma.
Varan A
Expert Rev Anticancer Ther; 2011 May; 11(5):771-80. PubMed ID: 21554052
[TBL] [Abstract][Full Text] [Related]
13. Medulloblastoma: what is the role of molecular genetics?
Entz-Werle N; Carli ED; Ducassou S; Legrain M; Grill J; Dufour C
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1169-81. PubMed ID: 18588461
[TBL] [Abstract][Full Text] [Related]
14. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification.
Polkinghorn WR; Tarbell NJ
Nat Clin Pract Oncol; 2007 May; 4(5):295-304. PubMed ID: 17464337
[TBL] [Abstract][Full Text] [Related]
15. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
16. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression.
de Haas T; Hasselt N; Troost D; Caron H; Popovic M; Zadravec-Zaletel L; Grajkowska W; Perek M; Osterheld MC; Ellison D; Baas F; Versteeg R; Kool M
Clin Cancer Res; 2008 Jul; 14(13):4154-60. PubMed ID: 18593994
[TBL] [Abstract][Full Text] [Related]
17. Childhood medulloblastoma.
Massimino M; Giangaspero F; Garrè ML; Gandola L; Poggi G; Biassoni V; Gatta G; Rutkowski S
Crit Rev Oncol Hematol; 2011 Jul; 79(1):65-83. PubMed ID: 21129995
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts.
Freeman CR; Taylor RE; Kortmann RD; Carrie C
Med Pediatr Oncol; 2002 Aug; 39(2):99-108. PubMed ID: 12116057
[TBL] [Abstract][Full Text] [Related]
19. Histological variants of medulloblastoma are the most powerful clinical prognostic indicators.
Massimino M; Antonelli M; Gandola L; Miceli R; Pollo B; Biassoni V; Schiavello E; Buttarelli FR; Spreafico F; Collini P; Giangaspero F
Pediatr Blood Cancer; 2013 Feb; 60(2):210-6. PubMed ID: 22693015
[TBL] [Abstract][Full Text] [Related]
20. Review of the prognostic factors in medulloblastoma of children and adults.
Brandes AA; Paris MK
Crit Rev Oncol Hematol; 2004 May; 50(2):121-8. PubMed ID: 15157661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
